JPS635379B2 - - Google Patents
Info
- Publication number
- JPS635379B2 JPS635379B2 JP53082139A JP8213978A JPS635379B2 JP S635379 B2 JPS635379 B2 JP S635379B2 JP 53082139 A JP53082139 A JP 53082139A JP 8213978 A JP8213978 A JP 8213978A JP S635379 B2 JPS635379 B2 JP S635379B2
- Authority
- JP
- Japan
- Prior art keywords
- particles
- cancer
- cancer cells
- composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 136
- 201000011510 cancer Diseases 0.000 claims description 127
- 239000002245 particle Substances 0.000 claims description 76
- 238000011282 treatment Methods 0.000 claims description 26
- 230000006698 induction Effects 0.000 claims description 23
- 238000010438 heat treatment Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- 239000002246 antineoplastic agent Substances 0.000 claims description 19
- 229940127089 cytotoxic agent Drugs 0.000 claims description 19
- 230000005672 electromagnetic field Effects 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000008247 solid mixture Substances 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 230000003834 intracellular effect Effects 0.000 claims description 10
- 230000002285 radioactive effect Effects 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- 230000005294 ferromagnetic effect Effects 0.000 claims description 8
- 230000005292 diamagnetic effect Effects 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 229960004887 ferric hydroxide Drugs 0.000 claims description 5
- 229940006110 gallium-67 Drugs 0.000 claims description 5
- 238000010253 intravenous injection Methods 0.000 claims description 5
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 claims description 5
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical group [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 230000005298 paramagnetic effect Effects 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- BUGBHKTXTAQXES-AHCXROLUSA-N Selenium-75 Chemical compound [75Se] BUGBHKTXTAQXES-AHCXROLUSA-N 0.000 claims description 2
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229940056501 technetium 99m Drugs 0.000 claims description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 152
- 238000000034 method Methods 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 17
- 238000000635 electron micrograph Methods 0.000 description 12
- 239000006249 magnetic particle Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 241000700159 Rattus Species 0.000 description 9
- 239000011859 microparticle Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229910052733 gallium Inorganic materials 0.000 description 5
- 108010077544 Chromatin Proteins 0.000 description 4
- 206010020843 Hyperthermia Diseases 0.000 description 4
- 210000003483 chromatin Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003302 ferromagnetic material Substances 0.000 description 4
- 230000036031 hyperthermia Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002411 adverse Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000002889 diamagnetic material Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000002907 paramagnetic material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- -1 indium-113m Chemical compound 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- YEEGWNXDUZONAA-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-gallabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Ga+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YEEGWNXDUZONAA-UHFFFAOYSA-K 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- DJHGAFSJWGLOIV-UHFFFAOYSA-K Arsenate3- Chemical compound [O-][As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-K 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229940000489 arsenate Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- OUFRIWNNMFWZTM-UHFFFAOYSA-M sodium arsanilate Chemical group [Na+].NC1=CC=C([As](O)([O-])=O)C=C1 OUFRIWNNMFWZTM-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8213978A JPS5511509A (en) | 1978-07-07 | 1978-07-07 | Cancer therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8213978A JPS5511509A (en) | 1978-07-07 | 1978-07-07 | Cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5511509A JPS5511509A (en) | 1980-01-26 |
| JPS635379B2 true JPS635379B2 (zh) | 1988-02-03 |
Family
ID=13766081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8213978A Granted JPS5511509A (en) | 1978-07-07 | 1978-07-07 | Cancer therapy |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5511509A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990001939A1 (en) * | 1988-08-19 | 1990-03-08 | Meito Sangyo Kabushiki Kaisha | Agent for thermotherapy |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55160720A (en) * | 1979-05-29 | 1980-12-13 | Mochida Pharmaceut Co Ltd | Remedial composition for cancer and its remedial device |
| JPS61128983A (ja) * | 1984-11-27 | 1986-06-17 | 大山 國賀 | 生体内の微粉を一定期間その位置に固定且微粉を任意の温度に発熱する方法 |
| JPS61265153A (ja) * | 1985-05-21 | 1986-11-22 | 高木 征一 | 温熱治療用被誘導加熱体 |
| JPS6412545U (zh) * | 1987-07-13 | 1989-01-23 | ||
| ATE371460T1 (de) | 2003-01-31 | 2007-09-15 | Otsuka Pharma Co Ltd | Hilfsstoff zum einsatz bei der krebstherapie mittels dielektrischer erwärmung und krebstherapieverfahren |
| EP1632225A4 (en) * | 2003-06-11 | 2007-08-15 | Nara Machinery Co Ltd | DRUG NANOPARTICLE, PROCESS AND APPARATUS FOR PREPARING PHARMACEUTICAL PREPARATION THEREFROM |
| US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| US20140308260A1 (en) | 2011-10-07 | 2014-10-16 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
| US10342778B1 (en) | 2015-10-20 | 2019-07-09 | Epicentrx, Inc. | Treatment of brain metastases using organonitro compound combination therapy |
| US9987270B1 (en) | 2015-10-29 | 2018-06-05 | Epicentrix, Inc. | Treatment of gliomas using organonitro compound combination therapy |
| KR20190040931A (ko) | 2016-01-11 | 2019-04-19 | 에피센트알엑스, 인코포레이티드 | 2-브로모-1-(3,3-디니트로아제티딘-1-일)에타논의 정맥내 투여를 위한 조성물 및 방법 |
| BR112019007453A2 (pt) | 2016-10-14 | 2019-07-16 | Epicentrx Inc | organonitro de sulfoxialquila e compostos relacionados e composições farmacêuticas para uso em medicina |
| IL271777B1 (en) | 2017-07-07 | 2024-05-01 | Epicentrx Inc | Preparations for intravenous administration of medical substances |
| WO2019164593A2 (en) | 2018-01-08 | 2019-08-29 | Epicentrx, Inc. | Methods and compositions utilizing rrx-001 combination therapy for radioprotection |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5649889A (en) * | 1979-10-01 | 1981-05-06 | Hiroshi Tanigaki | Cooler |
-
1978
- 1978-07-07 JP JP8213978A patent/JPS5511509A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5649889A (en) * | 1979-10-01 | 1981-05-06 | Hiroshi Tanigaki | Cooler |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990001939A1 (en) * | 1988-08-19 | 1990-03-08 | Meito Sangyo Kabushiki Kaisha | Agent for thermotherapy |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5511509A (en) | 1980-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4106488A (en) | Cancer treatment method | |
| US4303636A (en) | Cancer treatment | |
| Gordon et al. | Intracellular hyperthermia a biophysical approach to cancer treatment via intracellular temperature and biophysical alterations | |
| Gao et al. | Local hyperthermia in head and neck cancer: mechanism, application and advance | |
| US4359453A (en) | Atherosclerosis treatment method | |
| JP3677399B2 (ja) | 患者の病変組織の部位特異的な治療方法に使用するための磁性体及びヒステリシス療法に使用するための装置 | |
| EP0952873B1 (en) | Use of a magnetic material for the manufacture of a medicament for use in targeted hysteresis hyperthermia | |
| US4569836A (en) | Cancer treatment by intracellular hyperthermia | |
| JPS635379B2 (zh) | ||
| US20080213382A1 (en) | Thermotherapy susceptors and methods of using same | |
| Nikiforov et al. | Biomedical applications of magnetic nanoparticles | |
| US20070243137A1 (en) | Cell and sub-cell methods for imaging and therapy | |
| JP2009513722A (ja) | 磁性ナノスケール粒子組成物、及びそれに関連した治療方法 | |
| Nedelcu | Magnetic nanoparticles impact on tumoral cells in the treatment by magnetic fluid hyperthermia | |
| Binns | Medical applications of magnetic nanoparticles | |
| Kwizera et al. | Magnetic nanoparticle-mediated heating for biomedical applications | |
| Caizer | Magnetic hyperthermia-using magnetic metal/oxide nanoparticles with potential in cancer therapy | |
| WO2021083370A1 (zh) | 一种特异性激活免疫系统的纳米材料的制备和应用 | |
| Shinkai et al. | Effect of functional magnetic particles on radiofrequency capacitive heating: an in vivo study | |
| Fu et al. | Spatiotemporally Controlled Formation and Rotation of Magnetic Nanochains In Vivo for Precise Mechanotherapy of Tumors | |
| Aggarwal et al. | Magnetic drug delivery in therapeutics | |
| DE2828941C2 (zh) | ||
| US20080053912A1 (en) | Unipolar magnetic medicine carrier | |
| Zhang et al. | Recent advances in functionalized ferrite nanoparticles: from fundamentals to magnetic hyperthermia cancer therapy | |
| Fullerton | Hyperthermia as a Cancer Treatment-From Theory to Practice |